Healthcare Industry News: antiplatelet therapy
News Release - December 2, 2010
OrbusNeich's Genous Stent Shows Favorable Outcomes for Treatment of Coronary Artery Bifurcation Lesions Compared to Bare Metal StentsResults Published in Atherosclerosis Show Low Composite Rate of Cardiac Death, Myocardial Infarction or Target Lesion Revascularization in Patients Treated with Genous Stent
HONG KONG, Dec. 2, 2010 -- (Healthcare Sales & Marketing Network) -- OrbusNeich's Genous Stent shows favorable outcomes compared to bare metal stents (BMS) for the treatment of coronary artery bifurcation lesions, according to data published online in the journal Atherosclerosis.
The cumulative rate of the study's primary endpoint, the composite of cardiac death, myocardial infarction (MI) or target lesion revascularization (TLR) at one year follow-up, was 12.4% in patients treated with a Genous Stent, a 30% reduction compared to 17.2% for the control group treated with BMS. The definite or probable stent thrombosis (ST) rate was 1.7% for the Genous Stent patient group, compared to 3.4% for the BMS treated patient group.
"Interventional cardiologists continue to be challenged by the 15 to 20% of all percutaneous coronary interventions that involve coronary artery bifurcation lesions," said Marcel Beijk, M.D., of the Academic Medical Center in Amsterdam, the lead author of the paper. "The results of this large study of provisional T-stenting using the Genous Stent are extremely encouraging. The endothelial progenitor cell capture stent provides an excellent alternative to bare metal stents for the treatment of these challenging lesions."
The paper, titled "One-year clinical outcome after provisional T-stenting for bifurcation lesions with the endothelial progenitor cell capturing stent compared with the bare-metal stent," is based on a single-center, non-randomized study. The study involved 178 consecutive patients who underwent percutaneous coronary intervention for a de novo bifurcation lesion treated with a Genous Stent and 465 consecutive patients treated with BMS.
Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.
The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 5,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.
OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as stents, balloons and guiding catheters marketed under the names of Blazer™, R stent, Scoreflex™, Sapphire™ and Sapphire NC. Development stage products include the Combo™ Bio-engineered Sirolimus Eluting Stent, or Combo Stent, which combines the Genous pro-healing technology for rapid endothelial coverage with an abluminal sirolimus drug elution for the control of neointimal proliferation. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.